Latest news for Destiny Pharma (OTC:DTTYF) Stock

Destiny Pharma PLC is a clinical-stage biotechnology company that is focused on the development of medicines for the treatment of infectious diseases. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. It is involved in developing XF-73 Dermal for the treatment of skin infections of antibiotic-resistant bacteria, XF-73 Nasal for the prevention of post-surgical staphylococcal infection, and NTCD-M3 among others.

DESTINY PHARMA HLDGS PLC by Destiny Pharma Hldgs PLC

Destiny Pharma PLC

RBC Capital analyst Daniel Perlin maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Outperform and raises the price target from $180 to $183.

News

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Fiserv, Raises Price Target to $183

JP Morgan analyst Richard Choe maintains AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) with a Overweight and raises the price target from $21 to $24.

JP Morgan Maintains Overweight on AT&T, Raises Price Target to $24

WIIM

KALU

Kaiser Aluminum shares are trading lower after the company reported worse-than-expected Q2 financial results.

Deutsche Bank analyst Steve Powers maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Hold and lowers the price target from $62 to $56.

Deutsche Bank Maintains Hold on Molson Coors Beverage, Lowers Price Target to $56

AMTB

Amerant Bancorp shares are trading lower after the company reported worse-than-expected Q2 earnings.

Deutsche Bank analyst Carlo Santarelli maintains Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) with a Buy and lowers the price target from $61 to $55.

Deutsche Bank Maintains Buy on Las Vegas Sands, Lowers Price Target to $55

Trading Ideas

ORKT

Orangekloud Technology Shares Halted On Circuit Breaker To The Upside

JP Morgan analyst Matthew Boss maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Overweight and lowers the price target from $457 to $338.

LULU

JP Morgan Maintains Overweight on Lululemon Athletica, Lowers Price Target to $338

Deutsche Bank analyst Steve Powers maintains Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) with a Buy and lowers the price target from $24 to $23.

KVUE

Deutsche Bank Maintains Buy on Kenvue, Lowers Price Target to $23

Deutsche Bank analyst Lauren Silberman maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Buy and lowers the price target from $72 to $67.

Deutsche Bank Maintains Buy on Chipotle Mexican Grill, Lowers Price Target to $67

RBC Capital analyst Deane Dray maintains Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) with a Sector Perform and lowers the price target from $83 to $77.

RBC Capital Maintains Sector Perform on Fortive, Lowers Price Target to $77

Deutsche Bank analyst Steve Powers maintains BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) with a Buy and lowers the price target from $67 to $65.

BRBR

Deutsche Bank Maintains Buy on BellRing Brands, Lowers Price Target to $65

Deutsche Bank analyst Pito Chickering maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Buy and lowers the price target from $103 to $85.

Deutsche Bank Maintains Buy on Edwards Lifesciences, Lowers Price Target to $85

Jefferies analyst Brent Thill maintains IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Hold and raises the price target from $190 to $200.

Jefferies Maintains Hold on IBM, Raises Price Target to $200

Craig-Hallum analyst Richard Shannon maintains MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) with a Hold and lowers the price target from $38 to $28.

Craig-Hallum Maintains Hold on MaxLinear, Lowers Price Target to $28

Craig-Hallum analyst Anthony Stoss maintains STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) with a Buy and lowers the price target from $48 to $42.

Craig-Hallum Maintains Buy on STMicroelectronics, Lowers Price Target to $42

Craig-Hallum analyst Christian Schwab upgrades Flex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) from Hold to Buy and raises the price target from $27 to $39.

Upgrades

FLEX

Craig-Hallum Upgrades Flex to Buy, Raises Price Target to $39

FFIV

F5 Named Vendor On DoD Enterprise Software Initiative BPA Awarded To Carahsoft Technology; Agreement Valid Through September 4, 2027

A trader on crypto-based prediction market Polymarket bet over $1 million on President Joe Biden not finishing his term, despite the President committing to the contrary in <a href="https://www.benzinga.com/news/24/07/39947087/biden-says-history-is-in-your-hands-in-oval-office-speech-the-best-way-forward-is-to-pass-the-torch">his Wednesday speech</a>.
What Happened: Besides betting $1 million on the President resigning early, &#8216;<a href="https://polymarket.com/profile/0x1d04d5b13ba31ca6f3b9526ded9cfe43519ced05">Anon1933</a>&#8216; also wagered over $100,000 on Biden resigning before July 31 and almost $20,000 on the President stepping down before the end of August. The trader is currently down over $300,000 on their positions.
Polymarket traders currently assign a <a href="https://polymarket.com/market/will-biden-complete-his-term-as-president">29% chance</a> the President does not serve out his term, a <a href="https://polymarket.com/market/will-biden-resign-by-july-31">2% chance</a> of a resignation before the end of the month and a <a href="https://polymarket.com/market/will-biden-announce-resignation-by-august-31">9% chance</a> of President Biden resigning by the end of August. 
Over $12 million has been traded on the market for President Biden to finish his term. Odds dropped as low as 46% on Monday amid rumors about the President&#8217;s health. President Biden did not address his health in his Wednesday speech, focusing instead on his legacy and the rationale for stepping back from being the Democratic nominee.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39880291/president-bidens-exit-followed-nearly-80m-in-wagers-on-crypto-prediction-market-polymarket">President Biden&#8217;s Exit Followed Nearly $80M In Wagers On Crypto Prediction Market Polymarket</a>
Why It Matters: Polymarket, a decentralized prediction markets platform, has shattered its monthly trading volume record in July, surpassing $275 million and highlighting the growing interest in crypto-based betting on political outcomes, The Block reported.
The platform&#8217;s unprecedented surge in activity is primarily driven by users eager to wager on U.S. political events.
Following President Biden&#8217;s withdrawal from the race, the platform indicates a <a href="https://polymarket.com/market/will-kamala-harris-win-the-2024-democratic-presidential-nomination">94% chance</a> for Vice President Kamala Harris to secure the Democratic nomination. Former White House official Anthony Scaramucci <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39948413/trump-era-white-house-official-anthony-scaramucci-says-kamala-harris-is-capable-and-has-a-">stated</a> he is looking forward to seeing her policies on crypto.  
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39916724/vice-president-kamala-harris-team-contacted-mark-cuban-on-crypto-policy">Vice President Kamala Harris&#8217; Team Contacted Mark Cuban On Crypto Policy</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Polymarket Trader Has Bet Over $1M On President Biden To Not Finish His Term: Here's How That Is Going

BMO Capital analyst Keith Bachman maintains Check Point Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) with a Market Perform and raises the price target from $180 to $200.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Destiny Pharma

News

Latest news for Destiny Pharma (OTC:DTTYF) Stock